A number of investigations have noted that functional biological assays for heparin are not always reliable and may not reflect the actual biochemical level of heparin in patients receiving anticoagulant therapy. This creates the possibility that patients receiving anticoagulant treatment may have an excess or deficiency of circulating levels of heparin. To address this problem, we have developed a direct biochemical measurement of heparin. The heparin assay uses fluorophoreassisted carbohydrate electrophoresis (FACE) to directly measure the predominate disaccharide of unfractionated heparin. In this study, unfractionated heparin was measured in vitro throughout a wide range of heparin concentrations in plasma. Seven in vivo pharmacokinetic studies in five normal subjects given 3,000 USP units of unfractionated heparin intravenously showed a three-phase elimination process with higher peak plasma levels and shorter elimination times than predicted from previous studies. At these doses, heparin is largely eliminated intact through urinary excretion. Body weight has a significant effect on heparin kinetics. When we compared the direct biochemical assay with two biological clotting assays, we found the latter can overestimate biochemical heparin concentrations. The FACE assay, due to its sensitivity, is also able to measure circulating levels of endogenous heparin in plasma and urine. Direct heparin measurement using the FACE technique is practical and useful for studies of the correlation of biochemical and biological activities.
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Heparin is a highly sulfated, long chain polysaccharide of N-acetyl-glucosamine alternating with glucuronic acid or iduronic acid with an average molecular weight in the unfractionated form in excess of 15,000 d. It functions as an anticoagulant by binding to antithrombin III (AT III). This complex greatly enhances the inhibition of thrombin and other activated clotting factors such as activated factor X (1) . The binding site of AT III to heparin is a unique pentasaccharide sequence found in the heparin molecule (2) . Heparin is also capable of releasing tissue factor pathway inhibitor (TFPI), a natural anticoagulant found in endothelial cells lining the blood vessels (3) . Because of this anticoagulant activity, heparin is used in the treatment of thrombotic disorders such as deep venous thrombosis (4) . Although the individual response to heparin is variable, its efficacy relies on a dose of heparin that will prevent further thrombus extension (5) (6) (7) . Inadequate initial treatment can lead to recurrent thromboembolic events (8) . Heparin has other biological activities, one of which may cause bleeding, a major complication of therapy (9) . This complication is most often encountered when the dose of heparin is in excess of that required to prevent further clot formation.
Heparin is produced commercially as a sodium salt from beef lung or pork intestinal mucosa. Pork heparin is most often used in the United States. Either source produces a similar clinical efficacy (10) . The potencies of various heparin preparations are variable (11), depending on the different manufacturers. Efforts to standardize heparin have been difficult. This is explained for the most part by the product variability and available indirect test methods (12, 13) . Indirect laboratory testing using activated partial thromboplastin time (aPTT) is used, for the most part, to monitor and adjust the dose of heparin necessary to maintain anticoagulation in the therapeutic range, as well as to reduce the possibility of bleeding complications. Unfortunately, the responsiveness of different aPTT reagents to heparin is inconsistent, and an ideal reagent has yet to be developed (14, 15) . Because individuals respond differently to heparin, the relationship between heparin dose and heparin blood levels cannot be predicted reliably by surrogate coagulation tests such as the aPTT (16) (17) (18) . Levine and co-workers (19) noted in patients requiring large amounts of heparin for treatment, that the aPTT does not always reflect actual heparin levels. By increasing the heparin required to reach therapeutic levels, the patient may be at further risk for bleeding complications. Heparin assay by protamine sulfate titration and anti-Xa suggests the amount of heparin needed to keep the heparin level in the therapeutic range is less. Erdman and co-workers (13) have stated that ideally, heparin therapy would be monitored with plasma heparin concentrations rather than by the aPTT (13) .
Although newer biochemical methods to assay for heparin have been developed using reversed phase high pressure liquid chromatography (20) , paper chromatography and cationic dye staining (21) , polyacrylamide gel electrophoresis (22) , mass spectrometry (23), nuclear magnetic resonance spectroscopy (24) , and electrochemical sensing (25) , little is known about the biochemical levels of heparin in plasma after administration. Some methods are not clinically applicable or are not heparin specific, and only a limited number of clinical studies have been conducted using these methods. Subsequently, little is known of the pharmacokinetics and biological elimination of intact heparin using biochemical assays.
To determine the pharmacokinetics and elimination of heparin in humans and to correlate indirect coagulation assay results with plasma heparin levels, we have developed a reproducible method for the direct biochemical measurement of heparin. Flurophore-assisted carbohydrate electrophoresis (FACER) provides high-resolution separation of subpicomolar quantities of the glycosaminoglycan heparin in plasma and urine. The technique can be used to measure the predominate biologically active disaccharide in heparin (26) . This study reports on the pharmacokinetics and clearance of heparin in normal subjects and compares the results with conventional clotting assays currently used in monitoring patients on anticoagulation therapy. This work has been presented in preliminary form (27) .
SUBJECTS AND METHODS
Five healthy volunteers ranging in age from 23 to 59 years were entered into the study following Institutional Review Board approval and informed consent. The study group consisted of four men and one woman. These subjects were determined, by prior laboratory testing, to have a normal coagulation system, were healthy, and were not taking any medications. Body weights varied from 60 to 100 kg. Subjects 1 and 2 underwent repeat testing approximately 1 month after the initial study and in subject 5, the initial blood samplings were separated into duplicate samples to evaluate reproducibility, accuracy, and precision of the assay system. Studies were performed in the hematology research laboratory of Sacred Heart Medical Center (Spokane, WA, U.S.A.). Blood samples were drawn from an indwelling catheter after flushing with normal saline into collection tubes with 3.2% buffer sodium citrate (Becton Dickinson, Rutherford, NJ, U.S.A.) or 7.5% EDTA anticoagulant. A bolus infusion of 3,000 units of unfractionated porcine heparin, lot #114063, (Elkins-Sinn, Cherry Hill, NJ, U.S.A.) was infused intravenously over three minutes. The catheter was flushed and maintained with a normal saline solution. Blood samples were drawn at baseline, just prior to heparin infusion, and at 10, 20, 30, 45, 60, 120, 180, and 240 min ( Fig. 1 ). In three of five subjects, a 5-minute sample was also obtained. Each blood sample was drawn via a three-way stopcock after the catheter was filled with aspirated venous blood. Urine samples were obtained at baseline, prior to infusion of heparin, and at 30, 60, 90, 120, 180, and 240 minutes in subjects 3, 4, and 5, and at baseline and 60 minutes in subjects 1 and 2 (Fig. 1 ). Assays for aPTT, prothrombin time (PT), thrombin time (TT), fibrinogen, and platelets were performed immediately following collection. Samples for the assay of AT III, anti-Xa, TFPI, and the FACE&reg; assay of plasma heparin were stored at -70°C until assayed. Urine samples were frozen at -20°C for the FACE&reg; assay for heparin.
Anticoagulated blood samples were stored on ice and plasma was separated at 4°C using a double-spin technique. Assays for aPTT, PT, TT, fibrinogen, and AT III were performed according to standard clinical laboratory procedures. An assay for total TFPI antigen was measured by enzyme-linked immunosorbent assay (ELISA) FIG. 1. Experimental design. The schedule of blood and urine samplings before and after the intravenous infusion of 3,000 units of unfractionated heparin in four male and one female volunteer subjects. The same schedule was used in two repeat studies in subjects 1 and 2.
(IMUBIND, American Diagnostica, Greenwich, CT, U.S.A.) and anti-Xa by chromogenic substrate (Chromostrate, Organon Teknika Corp., Durham, NC, U.S.A.). A complete automated blood cell and platelet count was performed on the EDTA-anticoagulated samples.
The IS-disaccharide fraction of heparin (aAUronic acid-2-S04-(1-4)N-acetyl-glucosamine-NS04-6S04) in plasma and urine was measured using FACE (28) . Samples were thawed at 37°C for 20 minutes. For plasma, a 100 pLL sample was extracted with 100 RL chloroform. The aqueous phase was adjusted to 2.0 M ammonium acetate and three volumes of ethanol were added. Following a 30-minute incubation on ice, the precipitate was recovered by centrifugation at 14,000g for 10 minutes. For urine, a 500 p,L sample was precipitated with an equal volume of 1 % CPC reagent. Pellets for both were dried in a centrifugal vacuum evaporator (CVE). Five microliters heparinase 1 (Glyko, Novato, CA, U.S.A.) was added, and the sample was incubated for 1 hour at 37°C. The digest was dried in a CVE and resuspended in 5 RL of the fluorophore 8-aminonaphthalene-1,3,6 trisulfonic acid (ANTS) 0.15 M in 15% acetic acid with 5 pLL 1 M NaCNBH4 in dimethyl sulfoxide (DMSO). The mixture was incubated for 16 hours at 37°C. Samples were dried and resuspended in 10 p,L water. Two microliters of the resuspended material were combined with 2 pill 30% glycerol. The entire 4 pLL was loaded onto a single lane of a precast 35% polyacrylamide slab gel (Glyko) and run at 15 mA constant current for 1-2 hours at 20°C.
Imaging of the gels was performed on the FACE imaging system (Glyko) with individual bands quantitated using software supplied with the imager. Standard curves for heparin were generated and standard disaccharides were used to quantitate the amount of trisulfated disaccharide common to heparin found in the sample. Results were obtained as picomoles of heparin disaccharide per milliliter and converted to units of heparin per milliliter using a standard curve of heparin in plasma or urine. The recommended therapeutic range for the treatment of venous thrombosis is a calibrated aPTT, which corresponds to a heparin level between 0.2 and 0.4 U/mL as determined by protamine titration (7) . This generally corresponds to an aPTT between 40 and 80 seconds. Another approach uses a chromogenic anti-Xa assay where the therapeutic range varies from 0.3 to 0.7 U/mL (2) . Data presented in the figures were corrected by using the baseline values to represent zero.
RESULTS
The FACE@ assay for reducing sugars is widely used for quantitation of oligosaccharides derived from glycoproteins, glycolipids, and proteoglycans (28) and has applications in multiple diseases (29) . Results of the assay for bovine lung heparin are shown in Fig. 2 . For heparin disaccharide analysis, the method was validated using various heparin pharmaceutical standards. A doseresponse study of the 1 S fraction of heparin is shown in Fig. 3 . In this assay, the number of units per milliliter of heparin in subject plasma at each time point was determined using the amount of heparin disaccharide recovered from normal plasma spiked with increasing amounts of bovine lung heparin (Upjohn, Kalamazoo, MI, U.S.A.). The dose-response of IS disaccharide was linear within the therapeutic range of heparin. The amount of heparin in subject plasma was determined at each time point by extrapolation from the dose-response plot. For example, a plasma sample containing 17 pmoles of the IS disaccharide, as measured by FACE, contains 0.15 U/mL plasma heparin. The assay sensitivity is 0.025 U/mL plasma, precision is 5.1 % coefficient of variation (CV) (n = 16), and recovery from plasma is >80%. The reproducibility of the assay was determined in subject 5 where duplicate samples were taken for the first 45 minutes. Samples were prepared and individually assayed with excellent reproducibility (r = 0.998) ( Table 1 ).
The pharmacokinetics of heparin clearance were determined in seven subject studies (five subjects and two repeat studies of subjects 1 and 2) following a 3,000 unit intravenous (IV) bolus of porcine heparin ( Fig. 4 ). Mean plasma heparin levels reached a peak within 5 minutes after the influsion of heparin. This represents the initial phase (alpha) that is driven primarily by the distribution of heparin and binding to the available pool of binding sites in the plasma and tissue. The mean peak heparin Duplicate samples were obtained during the first 45 minutes at intervals shown following intravenous infusion of 3,000 units of unfractionated heparin (r = 0.998; p = 0.000 via t test). When FACE plasma heparin levels were compared to aPTT (Fig. 5 ), a therapeutic window ranging from 0.2 to 0.4 U/mL was used to represent the optimal therapeutic range of anticoagulation. The FACE assay, which directly measures the predominate disaccharide of the heparin molecule, and aPTT activity peaked at 5 minutes. Heparin levels dropped rapidly out of the therapeutic window below the 0.2 U/mL level in approximately 40 minutes, while the corresponding aPTT level remained well within the therapeutic window at a level of approximately 0.3 U/mL. The aPTT did not fall below the 0.2 level until approximately 70 minutes. Both assays reached baseline in 180 minutes.
The plasma level of heparin appears to be inversely related to the body weight of the subject. The subject with the level of 0.16 U/mL at the 5-minute point weighed 100 kg, while the subject with a 5-minute level of 1.45 U/mL weighed 56.8 kg. This relationship occurred in six of the seven studies. The importance of the relationship between body weight and heparin-induced Biochemical heparin measurements and aPTT measured from the same sample at the same time points in seven subjects who were given 3,000 units of porcine heparin by intravenous infusion. aPTT, activated partial thromboplastin time; FACE, flurophore-assisted carbohydrate electrophoresis. anticoagulation is shown in Figs. 6 and 7 . The seven studies were separated into two groups. The first group (Fig. 6 ) weighed between 82 and 105 kg (five studies, three subjects) and the second group (Fig. 7) weighed between 57 and 62 kg (two studies, two subjects). In the higher weight group (Fig. 6 ), mean heparin levels fell within the therapeutic window for only the first 10 minutes, while the mean aPTT stayed within the therapeutic window for approximately 50 minutes. In the low weight group, there was a marked difference from the high weight group. FACE heparin levels and aPTT measurements immediately reached supratherapeutic levels and remained there for 35 minutes and 55 minutes, respectively, before entering the therapeutic range. The FACE heparin levels remained in the therapeutic range for ap- proximately 65 minutes while the aPTT remained for about 45 minutes. The higher weight group reached baseline values by 180 minutes and the lower weight group by 240 minutes.
Levels of anti-Xa activity were then compared to the aPTT, using a therapeutic range of 0.3-0.7 U/mL for anti-Xa activity (Fig. 8 ). Anti-Xa activity levels initially rose to just below the midpoint of the therapeutic range in five minutes. In contrast, the direct heparin levels and aPTT were outside the therapeutic window. Anti-Xa activity gradually decreased to fall out of the therapeutic range by approximately 35 minutes. Levels could not be measured after 180 minutes.
Plasma TFPI antigen rose rapidly to over four times baseline following the infusion of heparin (Fig. 9 ). The level peaked at 5 minutes along with the direct heparin measurement. In contrast to heparin levels, TFPI gradu- Comparison of mean biochemical FACE assay for heparin and TFPI levels in seven subject studies following a single 3,000 unit intravenous bolus of unfractionated heparin. Therapeutic range for heparin is 0.2-0.4 U/mL. FACE, flurophore-assisted carbohydrate electrophoresis; TFPI, tissue factor pathway inhibitor.
ally dropped out of the therapeutic range by approximately 70 minutes and was undetectable at 180 minutes. Assays of urine for heparin revealed surprising results. When urine samples were labeled directly with a flurorophore (8-aminonaphthalene-1,3,6 trisulfonic acid; ANTS) without using extraction or heparinase, intact heparin chains were detected (data not shown). Disaccharide and monosaccharide profile analysis also confirmed heparin in urine was chemically identical to plasma heparin (data not shown). Pharmacokinetic clearance of heparin in urine is shown in Fig. 10 . Quantitative recovery of heparin demonstrated that >80% of the amount of heparin infused was recovered in the urine over a 4-hour period. Also of note was the observation that heparin levels could be detected in the urine prior to the administration of heparin in six of the seven subjects with a mean level of 0.18 U/mL. The only subject for which baseline heparin levels were not detected was the female subject.
Baseline preinfusion plasma levels of heparin were also detected in two of the seven studies. Results were from two different male subjects with a mean level of 0.045 U/mL. This observation most likely represents endogenous production of heparin by subjects since none had previously been exposed to exogenous heparin. The mean aPTT was 27.1 seconds in the group where baseline levels of plasma heparin were absent, and 29.2 seconds where plasma levels were detected. Blood count and coagulation parameters were determined in the study subjects. There were no significant changes in hemoglobin or white blood count. Similarly, platelet count, fibrinogen, and AT III levels were normal throughout, but the prothrombin time was mildly influenced over the first 90 minutes with peak influence occurring at 5 minutes (Table 2 ).
DISCUSSION
The current study used the FACE@ disaccharide assay as a direct biochemical measurement of biologically active heparin. The predominant disaccharide in heparin was measured and quantitated using known standard structures. The dose-response was linear in the range required for clinical monitoring of patients receiving heparin. Confidence in this assay is based on the work of more than 1,000 clinical samples, plus the work of others analyzing glycosaminoglycan disaccharides (30) . The use of a heparinase enzyme, which is specific for the N-sulfated site in the heparin disaccharide and the specific separation of the digested disaccharides, makes this 
Pharmacokinetic studies
Most studies of the pharmacokinetics of heparin in humans have relied directly or indirectly on biological (clotting) assays to measure the anticoagulant activity of heparin, or have depended upon ion exchange chromatography and/or cationic dye staining techniques, which may not be specific for heparin. The current study supports a unique triphasic elimination curve as reported by Wacksman et al. (31) and others (32, 33) . These studies, based on a direct biochemical assay, differ from previously reported studies where indirect biological assays in normal subjects were used (10, 11) . In both instances, based on the biological assay, the half-life increases with the dosage of heparin (34) . The results of these studies have been interpreted to represent a combination of a saturable and first-order mechanism for the disappearance of heparin. The current studies only partially support the model of an initial phase of rapid elimination representing distribution, and a secondary phase representing a nonlinear removal of heparin from the circulation. Wacksman and co-workers (31) have used computer simulation and direct heparin measurements in normal subjects from this study to demonstrate the unique triphasic elimination of heparin (Fig. 4 ). They, as well as others, found that biokinetics change with dose, clinical condition, and length of administration (31, (35) (36) (37) (38) . Small intravenous doses of heparin produce purely firstorder pharmacokinetic curves while larger doses produce a triphasic elimination curve. The initial and terminal phase decline in plasma concentrations are rapid, loglinear, and approximately equivalent, but are separated by an intermediate phase which has characteristics of zero-order elimination (31, 32, 39) .
The half-life of circulating heparin has been studied by numerous investigators and the results have been quite variable (32, 40, 41) . This is most likely explained by multiple variables, which can influence the plasma halflife, and the lack of suitable, rapid direct chemical assay for heparin (2, 8, 13) . As the dose of heparin increases, so doses the half-life of circulating heparin (34) , while the opposite occurs in the presence of extensive thrombosis such as a massive pulmonary embolism (42) . This variable anticoagulant response in acute disease processes most likely reflects the binding of heparin to plasma proteins (43) . In both instances, dosage adjustment is critical to patient outcome. The direct measurement of heparin using the FACE@ assay shows the half-life to be shorter than previously reported. Within a 15-minute period, half of the circulating heparin had been removed from the circulation (Fig. 4 ). This occurs during the distribution phase. The second or elimination phase half-life is about 45 minutes. During this elimination phase, hep-arin is easily measured in the urine. By 180 minutes (Fig.  4 ), heparin is no longer detected in the circulation.
There have been many studies to explain the elimination of heparin with results showing a wide variation. A common explanation states that heparin is cleared from the circulation by the reticuloendothelial system and metabolized by the liver. Breakdown products are then excreted in the urine (44, 45) . Another study reported that heparin is removed from the circulation intact, free form, and not bound to AT III (44) . Still others have noted the presence of heparin metabolic products in the urine (46) . Our findings provide new information that may explain the elimination of heparin from the circulation. After an infusion of a modest dose of heparin, a rapid appearance of largely intact heparin in the urine was observed. This is consistent with studies in dogs which showed, following large intravenous doses of heparin, intact (active as anticoagulants) heparin to be found in the urine (42) . By measuring sulfated heparin disaccharides using monosaccharide analysis, and by characterizing heparin directly without enzymolysis, this study has demonstrated that heparin, which appears in the urine of these subjects, is still highly sulfated, of high molecular weight, and chemically identical to the injected material. This rapid appearance of relatively intact heparin suggests a renal tubular transport mechanism. Singledose elimination studies would need to be supplemented with continuous-infusion studies to confirm this observation. Although peak concentrations of heparin in the urine were observed at 30 minutes, they may have occurred earlier since the first sample was taken at 30 minutes.
Biological versus biochemical assays
When mean heparin levels were plotted from the seven studies and compared to the aPTT, we found a difference between the two assays. Using the &dquo;therapeutic window&dquo; of 0.2-0.4 U/mL of heparin and a corresponding aPTT range between 40 and 80 seconds (1.5 to 3 times baseline), we noted a disparity after the initial peak of 5 minutes (Fig. 5 ). During the intermediate phase of heparin elimination, the FACE&reg; plasma heparin concentrations fell below the therapeutic window nearly 30 minutes before the aPTT did. This suggests an important disparity since the aPTT shows heparin activity to be in the therapeutic range at a time when the direct assay shows the heparin levels to be outside the therapeutic range. This observation supports the conclusion of Baker and co-workers (16) that heparin levels cannot be accurately predicted using the aPTT. Another observation shows the importance of body weight on the kinetics of heparin. Other investigators, using coagulation assays (47) , have documented this influence, but this is the first time a biochemical assay has been used. When the study subjects were divided into two groups, one with weights between 82 and 105 kg (high weight group) and the other between 57 and 62 kg (low weight group), significant differences were seen. In the high weight group, the direct heparin assay was only transiently in the therapeutic range during the first 5-10 minutes. However, the aPTT was indicating a higher concentration of heparin in the subjects, remaining within the therapeutic range for approximately 50 minutes. In the lower weight group, the results were quite different. The aPTT and FACE heparin levels initially rose well above the upper therapeutic range (Fig. 7 ) and remained within this range for the first 35 minutes (FACE@) and first 55 minutes (aPTT) following heparin infusion. Whereas FACE&reg; heparin was only transiently detected in the therapeutic range in the high weight group, it was detected either above or within the therapeutic range for nearly 90 minutes in the low weight group. In addition, aPTT levels more closely paralleled heparin levels in the low weight group.
The anti-Xa assay was evaluated using a therapeutic range of 0.3-0.7 U/mL (48) in a manner similar to the aPTT (Fig. 8 ). Anti-Xa levels peaked just below the midpoint of the therapeutic range and fell outside this range for approximately 20 minutes before aPTT levels did. Thus, monitoring a patient with the aPTT would suggest the patient is adequately anticoagulated at a time when the direct assay and anti-Xa levels would not support this. Anti-Xa levels and the direct assay for heparin are similar with the former indicating therapeutic anticoagulation for approximately 10 minutes longer than the direct assay. Because of the difficulties with the aPTT, the anti-Xa assay has been touted to be a replacement for the aPTT (16, 48) . Others have observed discrepancies between biological assays for heparin in normal human subjects given similar doses of heparin (16, 32, 49) . These studies point out some of the problems with the biological assays of heparin and support the need for a direct assay.
Levels of TFPI were dramatically increased by the infusion of heparin ( Fig. 9 ). Tissue factor pathway inhibitor is important as an inhibitor of the initial stages of coagulation activation, and is a direct inhibitor of factor Xa (50) . The complex inhibits the extrinsic coagulation system by inhibition of the Vlla-tissue factor complex (51, 52) . Levels of TFPI appeared and disappeared from the circulation in a manner similar to heparin and anti-Xa by dropping to baseline values at 180 minutes. The major difference between the direct heparin assay and the anti-Xa level is that anti-Xa levels remained elevated much longer. This elevation suggests heparin is present in the therapeutic range when, in fact, direct measurement of heparin fails to support this. Perhaps this observation can be explained by the influence of heparin on the release of TFPI, and may also explain discrepancies between heparin disaccharide and the aPTT, which remains prolonged after heparin is cleared. Tissue factor pathway inhibitor released by heparin has been shown to prolong the aPTT as will the addition of TFPI alone to plasma (53) . In addition, TFPI is a direct inhibitor of Xa and will prolong the anti-Xa assay (43) as the concentration of heparin is increased; there is a corresponding linear prolongation of the aPTT (54) . As the concentration of heparin is reduced during the process of elimination, the concentration of TFPI remains in the therapeutic range for a longer period as is reflected by the coagulation assays.
Endogenous heparin
Another interesting observation was the presence of measurable amounts of heparin in baseline samples of urine in six of the seven subjects. Since none of these subjects had previously been exposed to exogenous heparin, it is intriguing to suggest this most likely represents the excretion of endogenous heparin. In general, endogenous heparin has not been appreciated, even though its presence has been suspected for some time since mast cells contain active heparin (55) . Endogenous heparin has not been identified in clinical situations except in extreme conditions such as systemic mastocytosis where heparin is indirectly measured by a slight prolongation of the aPTT (56) .
Heparin sulfate (HS) is a closely related glycosaminoglycan, produced from the same precursor as heparin suggesting both substances may be measured with the 1 S disaccharide assay. Both have anticoagulant activities and the mechanism of action on AT III is similar with HS requiring higher concentrations for equivalent activity. However, despite the similarities there are significant differences. Heparin is found intracellularly in the secretory granules of mast cells and thus is found in a large number of organs. Heparan sulfate is found on the surface of endothelial cells and in the extracellular matrix of the subendothelium where it is believed to act as a natural anticoagulant for the endothelium. During the synthesis of HS, there is less modification of the repeating disaccharide precursors than in the synthesis of heparin. This results in a polymer with higher proportions of glucuronic acid and N-acetylglucosamine with fewer sulfate groups. However, heparin is highly sulfated. The binding site for antithrombin activation by heparin is a specific pentasaccharide whose sequence requires a 3-0-sulfated residue. In our assay, we measure the 1S disaccharide, which is the result of the action of a specific heparinase digestion on the disaccharide unit, a-L-iduronic acid 2-sulfate-((31-4) 2-deoxy-2-sulfamino-a.-D-glucose 6- sulfate. These residues are not present in HS.
The significance of endogenous heparin is unclear, but may play a role in the modulation of the hemostatic process, especially through the inactivation or inhibition of factors responsible for the integrity of the system. This concept is compelling because of the work of Engelberg (57) who was able to measure endogenous heparin and later showed that endogenous heparin levels were inversely related to cholesterol and lipoprotein levels (58) . A deficiency may therefore be a major factor in the pathogenesis of atherosclerosis (59) . Recently, it has been shown that reduced lipoprotein lipase (LPL) activity results in lower levels of high-density lipoproteins with the resultant increased susceptibility to coronary artery atherosclerosis (60) . If heparin is not available for LPL binding, loss of function results in elevation of lowdensity lipoproteins (61) . The implication of this observation and the relationship to atherosclerosis needs to be studied further.
CONCLUSION
The measurement of heparin in plasma and urine has direct consequences for the adjustment of heparin dosage in patients with an existing thrombosis. The importance of the renal clearance of heparin has been known for some time (1, 62) with individual patient reactions to heparin therapy varying widely. Thus, the optimal dose for any given patient must be determined by trial and error. The development of consistent and reliable biochemical assays for heparin and its subcomponents may contribute to a better understanding of the role of clotting-based assays in patient management, and possibly to the development of more efficient methods for determining the dose of heparin in a patient. In addition, with the direct measurement of heparin, the agonizing problems of the standardization of manufactured heparin products may be eliminated, as well as the problems of removing plasma from cells, plasma to citrate anticoagulant, and the timely freezing of the sample.
We conclude that biochemical measurement of heparin in plasma and urine is a practical method that can be used for the quantitative measurement of heparin. This assay measures the natural, unique biochemical domain of heparin, which can catalyze AT III neutralization of thrombin and activated serine proteases. We believe this assay may be a useful tool for studies of the correlation of biochemical and biological activities. The increased sensitivity of the assay now makes it possible to measure endogenous production of heparin in the blood and urine (63) . Although this is a pilot study of only five subjects, the results can pave the way for future investigations where the correlation of biochemical heparin levels with pharmacological effects during anticoagulation can be evaluated. Future studies with larger numbers of subjects will be needed to study multidosing, continuous infusion, and clinical conditions.
